H3.3K27M TCR T cell therapy / University of California, Gilead - LARVOL DELTA

Novel nanoparticle-based delivery of H3.3K27M peptide to tumor-associated macrophages enhances the tumor homing of H3.3K27M-TCR transduced T-cells in HLA-A2/DR1 transgenic mice with H3.3K27M (SNO 2021) - "HLA-A2/HLA-DR1 -transgenic mice bearing day 16 intracerebral H3.3K27M+ glioma received an intravenous administration of the CHP nanogel along with poly-ICLC, a Toll-like receptor 3 agonist. Furthermore, TAMs isolated from CHP-treated mice showed evidence of CHP-uptake, abilities to stimulate proliferation of TCR-transduced T-cells, and higher levels of HLA.A2 expression. These results suggest that the antigen-loaded CHP nanogel can promote the local antigen-presentation to T-cells and represent a promising approach for improving the efficacy of adoptive T-cell therapy for gliomas."

IO biomarker • Preclinical • Brain Cancer • Glioma • Oncology • Solid Tumor • CD8 • HLA-A